Replies to post #288 on Novocure Ltd (NVCR)

[jondoeuk]

Your information is incorrect about the DCVax-L cell-based platform technology.

No, it is not.

You need to seek better sources.

We know from the company itself and the clinical trials registry history that the trial was randomised and placebo controlled. Also, that the primary endpoint was PFS and the secondary endpoint was OS.

Last year Dr. Mulholland presented at the New York Academy of Sciences. For PFS, the hazard ratio was 1.1. So those in the vaccine arm did worse than placebo. They did not report the hazard ratio for OS, but the blended mOS was 23.1 months for placebo, while for the vaccine arm it was 22.4 months. This means the vaccine did worse than placebo. So, the trend was to harm, not benefit.

As for the JAMA Oncology paper, you should read the comments left. Also, various expert opinions and papers like these https://www.practiceupdate.com/c/5a1bf484-a4ad-467b-a962-d382404cf951 https://www.practiceupdate.com/c/de89dd7d-9c8f-45fb-aa08-27b5a4a07682 https://www.sciencedirect.com/science/article/pii/S0035378723009190 https://academic.oup.com/neuro-oncology/article/25/4/631/6958519 https://www.nature.com/articles/s41416-023-02194-1